A classification based on tumor budding and immune score for patients with hepatocellular carcinoma

References

• EASL Clinical Practice. Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–12. doi:10.1016/j.jhep.2018.03.019.
   PubMed Web of Science ®Google Scholar
• Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, Lee FY, Lin HC, Huo TI. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J Hepatol. 2016;64(3):601–608. doi:10.1016/j.jhep.2015.10.029.
   PubMed Web of Science ®Google Scholar
• Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245(6):909–922. doi:10.1097/01.sla.0000254368.65878.da.
   PubMed Web of Science ®Google Scholar
• Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, Chen MF. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114. doi:10.1186/1477-7819-9-114.
   PubMed Web of Science ®Google Scholar
• Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, et al. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer (Oxford, England: 1990). 2011;47(17):2568–2575. doi:10.1016/j.ejca.2011.07.002.
   PubMed Web of Science ®Google Scholar
• Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220(4):416–427. doi:10.1016/j.jamcollsurg.2014.12.025.
   PubMed Web of Science ®Google Scholar
• Ryan E, Khaw YL, Creavin B, Geraghty R, Ryan EJ, Gibbons D, Hanly A, Martin ST, O’Connell PR, Winter DC, et al. Tumor budding and PDC grade are stage independent predictors of clinical outcome in mismatch repair deficient colorectal cancer. Am J Surg Pathol. 2018;42(1):60–68. doi:10.1097/PAS.0000000000000931.
   PubMed Web of Science ®Google Scholar
• van Wyk HC, Park J, Roxburgh C, Horgan P, Foulis A, McMillan DC. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. Cancer Treat Rev. 2015;41(2):151–159. doi:10.1016/j.ctrv.2014.12.007.
   PubMed Web of Science ®Google Scholar
• Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A, Puppa G, Sheahan K. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer. 2016;115(7):831–840. doi:10.1038/bjc.2016.274.
   PubMed Web of Science ®Google Scholar
• Ueno H, Hase K, Hashiguchi Y, Shimazaki H, Tanaka M, Miyake O, Masaki T, Shimada Y, Kinugasa Y, Mori Y, et al. Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters. Am J Surg Pathol. 2014;38(2):197–204. doi:10.1097/PAS.0000000000000113.
   PubMed Web of Science ®Google Scholar
• Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, El Zimaity H, Flejou JF, Hansen TP, Hartmann A, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathol. 2017;30(9):1299–1311. doi:10.1038/modpathol.2017.46.
   PubMed Web of Science ®Google Scholar
• Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br J Cancer. 2012;106(11):1713–1717. doi:10.1038/bjc.2012.127.
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Kikuchi E, Mikami S, Ogihara K, Matsumoto K, Miyajima A, Oya M. Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers. Cancer Sci. 2016;107(9):1338–1344. doi:10.1111/cas.12990.
   PubMed Web of Science ®Google Scholar
• Jesinghaus M, Boxberg M, Konukiewitz B, Slotta-Huspenina J, Schlitter AM, Steiger K, Specht K, Wieczorek K, Warth A, Schmidt T, et al. A novel grading system based on tumor budding and cell nest size is a strong predictor of patient outcome in esophageal squamous cell carcinoma. Am J Surg Pathol. 2017;41(8):1112–1120. doi:10.1097/PAS.0000000000000865.
   PubMed Web of Science ®Google Scholar
• Jesinghaus M, Bruhl F, Steiger K, Klare P, Reiser M, Scheiter A, Konukiewitz B, Kuhn P, Munch S, Quante M, et al. Cellular dissociation grading based on the parameters tumor budding and cell nest size in pretherapeutic biopsy specimens allows for prognostic patient stratification in esophageal squamous cell carcinoma independent from clinical staging. Am J Surg Pathol. 2019;43(5):618–627. doi:10.1097/PAS.0000000000001230.
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E, Wartenberg M, Zlobec I, Cibin S, Worni M, Gloor B, Lugli A. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. Histopathology. 2018;73(1):137–146. doi:10.1111/his.13508.
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A, Gennatas K, Gloor B, Lugli A. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer (Oxford, England: 1990). 2013;49(5):1032–1039. doi:10.1016/j.ejca.2012.10.022.
   PubMed Web of Science ®Google Scholar
• Wartenberg M, Cibin S, Zlobec I, Vassella E, Eppenberger-Castori S, Terracciano L, Eichmann MD, Worni M. Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance. Clin Cancer Res. 2018;24(18):4444–4454. doi:10.1158/1078-0432.CCR-17-3401.
   PubMed Web of Science ®Google Scholar
• Kemi N, Eskuri M, Ikalainen J, Karttunen TJ, Kauppila JH. Tumor budding and prognosis in gastric adenocarcinoma. Am J Surg Pathol. 2019;43(2):229–234. doi:10.1097/PAS.0000000000001181.
   PubMed Web of Science ®Google Scholar
• Yamada N, Sugai T, Eizuka M, Tsuchida K, Sugimoto R, Mue Y, Suzuki M, Osakabe M, Uesugi N, Ishida K, et al. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition. Hum Pathol. 2017;60:151–159. doi:10.1016/j.humpath.2016.10.007.
   PubMed Web of Science ®Google Scholar
• Wang C, Huang H, Huang Z, Wang A, Chen X, Huang L, Zhou X, Liu X. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med. 2011;40(7):545–551. doi:10.1111/j.1600-0714.2011.01041.x.
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E, Lugli A, Panayiotides I, Karakitsos P, Peros G, Rallis G, Patsouris ES, Terracciano L, Zlobec I. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology. 2010;57(2):233–243. doi:10.1111/j.1365-2559.2010.03615.x.
   PubMed Web of Science ®Google Scholar
• Miksch RC, Schoenberg MB. Prognostic impact of tumor-infiltrating lymphocytes and neutrophils on survival of patients with upfront resection of pancreatic cancer. Cancers (Basel). 2019 Jan 3;11(1). pii: E39. doi: 10.3390/cancers11010039.
   Google Scholar
• Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698–711. doi:10.1016/j.immuni.2016.02.025.
   PubMed Web of Science ®Google Scholar
• Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen J, van Vugt M, de Vries EGE, Schroder CP, Fehrmann RSN. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer. J Natl Cancer Inst. 2017;109(1). doi:10.1093/jnci/djx007.
   PubMedGoogle Scholar
• Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst. 2018;110(1). doi:10.1093/jnci/djx216.
   PubMedGoogle Scholar
• Sideras K, Biermann K, Verheij J, Takkenberg BR, Mancham S, Hansen BE, Schutz HM, de Man RA, Sprengers D, Buschow SI, et al. PD-L1, galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology. 2017;6(2):e1273309. doi:10.1080/2162402X.2016.1273309.
   PubMed Web of Science ®Google Scholar
• Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, Luciani A, Amaddeo G, Derman J, Charpy C, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol. 2019;70(1):58–65. doi:10.1016/j.jhep.2018.09.003.
   PubMed Web of Science ®Google Scholar
• Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4(5):419–430. doi:10.1158/2326-6066.CIR-15-0110.
   PubMed Web of Science ®Google Scholar
• Hu G, Wang S. Tumor-infiltrating CD45RO(+) memory T lymphocytes predict favorable clinical outcome in solid tumors. Sci Rep. 2017;7(1):10376. doi:10.1038/s41598-017-11122-2.
   PubMedGoogle Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatol (Baltimore, Md). 2018;68(3):1025–1041. doi:10.1002/hep.29904.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L, Ye G, Deng H, Mou T, Cai S, et al. ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2018;267(3):504–513. doi:10.1097/SLA.0000000000002116.
   PubMed Web of Science ®Google Scholar
• Li W, Li L, Minigalin D, Wu H. Anatomic mesohepatectomy versus extended hepatectomy for patients with centrally located hepatocellular carcinoma. HPB. 2018;20(6):530–537. doi:10.1016/j.hpb.2017.11.012.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O’Beirne J, Fox R, Skowronska A, Palmer D, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151.
   PubMed Web of Science ®Google Scholar
• Ueno H, Jones AM, Wilkinson KH, Jass JR, Talbot IC. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 2004;53(4):581–586. doi:10.1136/gut.2003.028365.
   PubMed Web of Science ®Google Scholar
• Graham RP, Vierkant RA, Tillmans LS, Wang AH, Laird PW, Weisenberger DJ, Lynch CF, French AJ, Slager SL, Raissian Y, et al. Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol. 2015;39(10):1340–1346. doi:10.1097/PAS.0000000000000504.
   PubMed Web of Science ®Google Scholar
• Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H. Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2018;24(13):3069–3078.
   Google Scholar
• Jiang Y, Xie J, Han Z, Liu W, Xi S, Huang L, Huang W, Lin T, Zhao L, Hu Y, et al. Immunomarker support vector machine classifier for prediction of gastric cancer survival and adjuvant chemotherapeutic benefit. Clin Cancer Res. 2018;24(22):5574–5584. doi:10.1158/1078-0432.CCR-18-0848.
   PubMed Web of Science ®Google Scholar
• Wolowich WR, Casavant MJ, Ekins BR. Phenylpropanolamine and hemorrhagic stroke. N Engl J Med. 2001;344(14):1094–1095. doi:10.1056/NEJM200104053441411.
   PubMedGoogle Scholar
• Church SE, Galon J. Tumor microenvironment and immunotherapy: the whole picture is better than a glimpse. Immunity. 2015;43(4):631–633. doi:10.1016/j.immuni.2015.10.004.
   PubMed Web of Science ®Google Scholar
• Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouze E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727–738. doi:10.1016/j.jhep.2017.05.014.
   PubMed Web of Science ®Google Scholar
• Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153(3):812–826. doi:10.1053/j.gastro.2017.06.007.
   PubMed Web of Science ®Google Scholar
• Hu G, Wang S, Cheng P. Tumor-infiltrating tryptase(+) mast cells predict unfavorable clinical outcome in solid tumors. Int J Cancer. 2018;142(4):813–821. doi:10.1002/ijc.31099.
   PubMed Web of Science ®Google Scholar
• Miao L, Liu Q, Lin CM, Luo C, Wang Y, Liu L, Yin W, Hu S, Kim WY, Huang L. Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors. Cancer Res. 2017;77(3):719–731. doi:10.1158/0008-5472.CAN-16-0866.
   PubMed Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, Lim TKH, Yeong J, Toh HC, Lee SY, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916–927. doi:10.1136/gutjnl-2018-316510.
   PubMed Web of Science ®Google Scholar
• Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G, Iezzi G, Spagnoli G, Bihl M, Terracciano L, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101(8):1382–1392. doi:10.1038/sj.bjc.6605318.
   PubMed Web of Science ®Google Scholar
• Lang-Schwarz C, Melcher B, Haumaier F, Lang-Schwarz K, Rupprecht T, Vieth M, Sterlacci W. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups. Hum Pathol. 2018;79:160–167. doi:10.1016/j.humpath.2018.05.010.
   PubMed Web of Science ®Google Scholar
• Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8(1):1738.
   Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–235. doi:10.1038/nature14404.
   PubMed Web of Science ®Google Scholar
• Spranger S, Gajewski TF. Tumor-intrinsic oncogene pathways mediating immune avoidance. Oncoimmunology. 2016;5(3):e1086862. doi:10.1080/2162402X.2015.1086862.
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM, et al. Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers. Clin Cancer Res. 2017;23(15):4429–4440. doi:10.1158/1078-0432.CCR-17-0162.
   PubMed Web of Science ®Google Scholar